- Home
- RMTI vs CHRS Comparison
RMTI vs CHRS Comparison
Compare RMTI & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMTI
- CHRS
- Stock Information
- Founded
- RMTI 1994
- CHRS 2010
- Country
- RMTI United States
- CHRS United States
- Employees
- RMTI N/A
- CHRS N/A
- Industry
- RMTI Biotechnology: Pharmaceutical Preparations
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RMTI Health Care
- CHRS Health Care
- Exchange
- RMTI Nasdaq
- CHRS Nasdaq
- Market Cap
- RMTI 138.1M
- CHRS 156.0M
- IPO Year
- RMTI 1998
- CHRS 2014
- Fundamental
- Price
- RMTI $3.64
- CHRS $1.04
- Analyst Decision
- RMTI Strong Buy
- CHRS Buy
- Analyst Count
- RMTI 2
- CHRS 6
- Target Price
- RMTI $7.00
- CHRS $7.10
- AVG Volume (30 Days)
- RMTI 788.1K
- CHRS 3.0M
- Earning Date
- RMTI 11-12-2024
- CHRS 11-04-2024
- Dividend Yield
- RMTI N/A
- CHRS N/A
- EPS Growth
- RMTI N/A
- CHRS N/A
- EPS
- RMTI N/A
- CHRS N/A
- Revenue
- RMTI $94,372,000.00
- CHRS $308,134,000.00
- Revenue This Year
- RMTI $22.20
- CHRS $5.18
- Revenue Next Year
- RMTI $8.76
- CHRS $16.86
- P/E Ratio
- RMTI N/A
- CHRS N/A
- Revenue Growth
- RMTI 24.58
- CHRS 69.37
- 52 Week Low
- RMTI $1.16
- CHRS $0.97
- 52 Week High
- RMTI $4.57
- CHRS $3.98
- Technical
- Relative Strength Index (RSI)
- RMTI 52.11
- CHRS 39.91
- Support Level
- RMTI $3.47
- CHRS $0.99
- Resistance Level
- RMTI $3.97
- CHRS $1.23
- Average True Range (ATR)
- RMTI 0.29
- CHRS 0.09
- MACD
- RMTI -0.09
- CHRS 0.01
- Stochastic Oscillator
- RMTI 15.45
- CHRS 25.78
About RMTI Rockwell Medical Inc.
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, and acid and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate among others.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.